AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Copolymers and modified polymers === Linear polyacrylamide is a water-soluble polymer. Other polar solvents include DMSO and various alcohols. Cross-linking can be introduced using N,N-methylenebisacrylamide. Some crosslinked materials are swellable but not soluble, i.e., they are hydrogels. Partial hydrolysis occurs at elevated temperatures in aqueous media, converting some amide substituents to carboxylates. This hydrolysis thus makes the polymer particularly hydrophilic. The polymer produced from N,N-dimethylacrylamide resists hydrolysis. Copolymers of acrylamide include those derived from acrylic acid.
=== Esports === Monster Energy also sponsors several individuals in the esports community, as well as esports associations. The company broke into esports with their sponsorship of Evil Geniuses, one of the premiere North American multi-game organizations. Monster Energy is affiliated with esports in North America, Asia, Europe, and Australia. Some of the organizations and individuals they support or have supported include the Australian organization "MindFreak", Paris Saint-Germain eSports, and the streamer TimTheTatman.
Bhagat Singh Thind stands as a significant milestone in U.S. legal history, shedding light on the intricate intersections of immigration, citizenship, and racial identity. It serves as a poignant reminder of the biases entrenched within immigration laws and the complexities of racial classifications in American society.
Sources: en.wikipedia.org
Another common example is the reaction of a primary amine or secondary amine with a carboxylic acid or with a carboxylic acid derivative to form an amide. This reaction is widely used, especially in the synthesis of peptides. On the simple addition of an amine to a carboxylic acid, a salt of the organic acid and base is obtained. To overcome this, the carboxylic acid first needs to be "activated". This is usually done by converting the acid into a more reactive derivative (i.e. anhydride, acid halide) or by using a coupling agent. In some cases, high temperatures (>200 °C) can overcome salt formation by driving off water, without the need for "activation" of the carboxyl group. The downside to this simple reaction is that the compounds may decompose at these elevated temperatures. The carboxylic acid derivatives can be esters, anhydrides, acid halides or any other activated species. The choice of activated carboxyl group or coupling agent can be very important in peptide synthesis, as using the wrong one can lead to racemization.
=== Legal status in weapons === In 1996, the International Court of Justice (ICJ) gave an advisory opinion on the "legality of the threat or use of nuclear weapons". This made it clear, in paragraphs 54–56, that international law on poisonous weapons—the Second Hague Declaration of 29 July 1899, Hague Convention IV of 18 October 1907 and the Geneva Protocol of 17 June 1925—did not cover nuclear weapons, because their prime or exclusive use was not to poison or asphyxiate. This ICJ opinion was about nuclear weapons, but the sentence "The terms have been understood, in the practice of States, in their ordinary sense as covering weapons whose prime, or even exclusive, effect is to poison or asphyxiate," also removes depleted uranium weaponry from coverage by the same treaties as their primary use is not to poison or asphyxiate, but to destroy materiel and kill soldiers through kinetic energy. The Sub-Commission on Prevention of Discrimination and Protection of Minorities of the United Nations Human Rights Commission, passed two motions—the first in 1996 and the second in 1997. They listed weapons of mass destruction, or weapons with indiscriminate effect, or of a nature to cause superfluous injury or unnecessary suffering and urged all states to curb the production and the spread of such weapons. Included in the list was weaponry containing depleted uranium. The committee authorized a working paper, in the context of human rights and humanitarian norms, of the weapons. The requested UN working paper was delivered in 2002 by Y. K. J.
Barred lambda - ƛ El (Cyrillic) – Л, л Fraser alphabet#Consonants Greek letters used in mathematics, science, and engineering Half-Life (series) Samsung, an electronics company that uses the glyph "Λ" in its logo as a styled "A".
Sources: en.wikipedia.org
=== FTIR as detector in chromatography === The speed of FTIR allows spectra to be obtained from compounds as they are separated by a gas chromatograph. However this technique is little used compared to GC-MS (gas chromatography-mass spectrometry) which is more sensitive. The GC-IR method is particularly useful for identifying isomers, which by their nature have identical masses. Liquid chromatography fractions are more difficult because of the solvent present. One notable exception is to measure chain branching as a function of molecular size in polyethylene using gel permeation chromatography, which is possible using chlorinated solvents that have no absorption in the area in question.
=== 210Po === Some prototype RTGs, first built in 1958 by the US Atomic Energy Commission, have used polonium-210. This isotope provides phenomenal power density (pure 210Po emits 140 W/g) because of its high decay rate, but has limited use because of its very short half-life of 138 days. A half-gram sample of 210Po reaches temperatures of over 500 °C (900 °F). As 210Po is a pure alpha-emitter and does not emit significant gamma or X-ray radiation, the shielding requirements are as low as those for 238Pu. While the short half-life also reduces the time during which accidental release to the environment is a concern, polonium-210 is extremely radiotoxic if ingested and can cause significant harm even in chemically inert forms, which pass through the digestive tract as a "foreign object". A common route of production (whether accidental or deliberate) is neutron irradiation of 209Bi, the only naturally occurring isotope of bismuth. It is this accidental production that is cited as an argument against the use of lead-bismuth eutectic as a coolant in liquid metal reactors. However, if a sufficient demand for polonium-210 exists, its extraction could be worthwhile similar to how tritium is economically recovered from the heavy water moderator in CANDUs.
Main reactor Ethylene oxide scrubber Ethylene oxide de-sorber Stripping and distillation column CO2 scrubber and CO2 de-scrubber Main Reactor: The main reactor consists of thousands of catalyst tubes in bundles. These tubes are generally 6 to 15 m (20 to 50 ft) long with an inner diameter of 20 to 50 mm (0.8 to 2.0 in). The catalyst packed in these tubes is in the form of spheres or rings of diameter 3 to 10 mm (0.12 to 0.39 in). The operating conditions of 200–300 °C (390–570 °F) with a pressure of 1–3 MPa (150–440 psi) prevail in the reactor. To maintain this temperature, the cooling system of the reactor plays a vital role. With the aging of the catalyst, its selectivity decreases and it produces more exothermic side products of CO2. Ethylene oxide scrubber: After the gaseous stream from the main reactor, containing ethylene oxide (1–2%) and CO2 (5%), is cooled, it is then passed to the ethylene oxide scrubber. Here, water is used as the scrubbing media which scrubs away majority of ethylene oxide along with some amounts of CO2, N2, CH2=CH2, CH4 and aldehydes (introduced by the recycle stream). Also, a small proportion of the gas leaving the ethylene oxide scrubber (0.1–0.2%) is removed continuously (combusted) to prevent the buildup of inert compounds (N2, Ar, and C2H6), which are introduced as impurities with the reactants. Ethylene oxide de-sorber: The aqueous stream resulting from the above scrubbing process is then sent to the ethylene oxide de-sorber.
Will Self, novelist (Jewish mother); son of Peter Self, and grandson of Sir Albert Henry Self Charles Gabriel Seligman FRS FRAI (né Seligmann; 24 December 1873 – 19 September 1940) was author, scholar, academic, physician and ethnologist; main ethnographic work described culture of Vedda people of Sri Lanka and Shilluk people of Sudan; was professor at London School of Economics; influential as the teacher of Bronisław Malinowski, E. E. Evans-Pritchard, and Meyer Fortes; was proponent of the Hamitic hypothesis, according to which some civilisations of Africa were thought to have been founded by Caucasoid Hamitic peoples. His work in the 1920s and 1930s is now seen as "white supremacist". Nicholas Serota (born 27 April 1946), author, art historian and curator; served as Director of the Tate from 1988 to 2017; currently Chair of Arts Council England; was previously Director of The Museum of Modern Art, Oxford, and Director of the Whitechapel Gallery, before becoming Director of the Tate; was also Chairman of the Turner Prize jury. Malcolm Shaw (academic) KC (born 1947), British legal academic, author, editor and lawyer; studied at University of Liverpool (LLB), Hebrew University of Jerusalem (LLM) and Keele University (PhD); was the Sir Robert Jennings Professor of International Law at the University of Leicester and taught international law, human rights and equity and trusts; appointed as Senior Fellow at Lauterpacht Centre for International Law at University of Cambridge; Trustee of the British Institute of International and Comparative Law.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.